SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K Current Report was filed by BioSig Technologies, Inc. on July 7, 2021. The registrant is incorporated in Delaware and trades on the NASDAQ Capital Market under the symbol BSGM. The report primarily serves as a Regulation FD disclosure regarding a specific business development.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report on a specific event and does not contain financial statements or performance metrics.
Material Changes
The material event disclosed is the installation of the Company's technology in a leading New York City hospital, as announced in a press release dated July 7, 2021 (Exhibit 99.1). No financial comparisons to prior periods are included in this filing.
Guidance, Outlook, and Risks
The Company explicitly states it undertakes no obligation to update, supplement, or amend the materials attached to this report. The filing includes standard disclaimers that the information is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not intended to constitute a determination of materiality under Regulation FD. No specific guidance, outlook, or risk factors are detailed in the body of this 8-K.
Investor Verification Checklist
- Verify the details of the hospital installation by reviewing the attached Press Release (Exhibit 99.1).
- Confirm the commercial terms and revenue impact of the New York City hospital deal, as these are not quantified in this filing.
- Review the Company's most recent 10-Q or 10-K for current financial health, liquidity, and debt levels.
- Monitor future filings for any updates on the commercialization of the technology in the New York market.